Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Surrozen, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q1 2023
- Shares held
- 15.7M
- −796.3K (−4.8%) vs. Q1 2023
- Total value
- $8.62M
- −$1.29M (−13.1%) vs. Q1 2023
- New holders
- 3
- 2 more added
- Sold out
- 4
- 5 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 589 | $0 | 0.00% | +589 | New |
| Wells Fargo & Company | 132 | $73 | 0.00% | −16−10.8% | Reduced |
| Wolverine Asset Management LLC | 7,725 | $4.25K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 8,425 | $4.63K | 0.00% | −8,763−51.0% | Reduced |
| HRT Financial LP | 16,271 | $8.00K | 0.00% | +16,271 | New |
| Prudential Financial Inc | 20,600 | $11.3K | 0.00% | +20,600 | New |
| Northern Trust Corp | 35,833 | $19.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 36,199 | $19.9K | 0.00% | −50,231−58.1% | Reduced |
| Jasper Ridge Partners, L.P. | 46,838 | $25.8K | 0.00% | 00.0% | Unchanged |
| Bridger Management, LLC | 61,699 | $33.9K | 0.01% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 61,699 | $33.9K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 70,932 | $39.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 113,698 | $63.0K | 0.00% | +11,400+11.1% | Added |
| Geode Capital Management, LLC | 171,950 | $94.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 487,698 | $268.2K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 528,180 | $290.5K | 0.00% | −261,690−33.1% | Reduced |
| Trustees of Columbia University in the City of New York | 718,950 | $395.4K | 0.58% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 781,960 | $430.1K | 0.04% | 00.0% | Unchanged |
| Euclidean Capital LLC | 802,963 | $441.6K | 0.11% | 00.0% | Unchanged |
| Harvard Management Co Inc | 826,852 | $455.0K | 0.04% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,459,084 | $802.5K | 0.72% | −34,953−2.3% | Reduced |
| The Column Group LLC | 9,414,795 | $5.18M | 2.01% | +166,666+1.8% | Added |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −305,648−100.0% | Sold out |
| Samsara BioCapital, LLC | 0 | $0 | 0.00% | −300,000−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −35,316−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −15,250−100.0% | Sold out |